Moderna to Report Second Quarter 2019 Financial Results on Wednesday, August 7th, 2019
July 24 2019 - 8:00AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that it will host a live conference call
and webcast at 8:00 a.m. ET on Wednesday, August 7, 2019 to report
its second quarter 2019 financial results and provide a corporate
update.
To access the live conference call, please dial 866-922-5184
(domestic) or 409-937-8950 (international), and refer to conference
ID 4799277. A webcast of the call will also be available under
“Events and Presentations” in the Investors section of the Moderna
website at https://investors.modernatx.com/. The archived webcast
will be available on Moderna’s website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that have a therapeutic or preventive
benefit with the potential to address a broad spectrum of diseases.
Moderna’s platform builds on continuous advances in basic and
applied mRNA science, delivery technology and manufacturing,
providing the Company the capability to pursue in parallel a robust
pipeline of new development candidates. Moderna is developing
therapeutics and vaccines for infectious diseases, immuno-oncology,
rare diseases and cardiovascular diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
and Merck, Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of Defense and the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been ranked in the top ten of Science’s
list of top biopharma industry employers for the past four years.
To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190724005087/en/
Investors: Lavina Talukdar Head, Investor Relations
617-209-5834 lavina.talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024